Designation, plausibility, protocol assistance, clinical benefit, similarity, reassessment: Rules and experiences

Article type: Research Article

Authors: Walker, Chris

Affiliations: Amgen International Regulatory Affairs, Cambridge, UK. E-mail: [email protected]

Abstract: Orphan legislation provides incentives to industry to investigate rare conditions that otherwise would be unlikely to be investigated. These incentives include, free access to scientific advice during the development of their clinical programs ('protocol assistance'); reduction in fees payable to EMA for review of the marketing authorisation and subsequent licence maintenance fees; sustained market protection in the form of market exclusivity in addition to a range of national incentives. To qualify for these incentives companies must apply for orphan designation confirming the seriousness of the condition which has inadequate alternative therapeutic options (for the diagnosis, prevention or treatment) and that the condition qualifies in terms of low prevalence in the European community. The company must also provide evidence of medical plausibility including likely significant medical benefit for patients to be treated with the product for the proposed orphan indication. If an application for orphan designation is not accepted then a company is able to appeal providing detailed grounds for reassessment and will receive a second opinion from the PDCO. The period of market exclusivity awarded by orphan designation will require that future applications received by the EMA for the same condition have to undergo an assessment of similarity to ensure that no variations or new applications for 'similar' medicinal products are granted licences during this ten year period. Products gaining orphan designation provide regular/annual reports regarding their development status, status of global regulatory submissions and any change likely financial returns predicted for the indication.

Keywords: Orphan designation, protocol assistance, incentives, similarities

DOI: 10.3233/PPL-2010-0269

Journal: Pharmaceuticals, Policy and Law, vol. 12, no. 1-2, pp. 67-70, 2010